The companies that we will target have the potential to be disruptive and primed for explosive growth and that can change the world for the better, while establishing a position of technological dominance. We believe we are well positioned to pursue initial business combination opportunities within our four domains of interest: Planet & Efficient Energy; Brain & […]

We intend to focus on identifying businesses that can benefit from our management team’s world-class operating experience in the consumer industry and over 30 years of combined experience in private equity investing. Our focus will be on the consumer industry but primarily “Innovative Consumer,” which is a focus on disruptive consumer companies utilizing technology and […]

Our efforts to identify a prospective target business will not be limited to a particular industry or geographic region, although the company intends to focus on opportunities in Asia (excluding China). We intend to primarily focus on fast-growing technology companies in different industry verticals, including but not limited to e-commerce, financial technology (FinTech), insurance technology, […]

(Note: IPOScoop has NO CALL on this deal. This is a NASDAQ uplisting. This is NOT an IPO, although the prospectus calls the deal an initial public offering of American Depositary Shares (ADS). Each ADS represents 180 ordinary shares. Bionomics Ltd.’s ordinary shares are listed on the Australian Securities Exchange (“ASX”), under the symbol “BNO.”) […]

NEXGEL is a leading provider of ultra-gentle high-water-content hydrogels for healthcare and consumer applications. We have developed and manufactured electron-beam cross-linked hydrogels for over two decades. Alongside our strategic partners, NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with […]

We are a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics (“TSTx”)TM in oncology and inflammation. Our lead product candidate, IMX-110, is currently in Phase 1b/2a clinical trials for solid tumors in the United States and Australia. IMX-110 is a negatively-charged TSTx that simultaneously disables resistance pathways with a poly-kinase inhibitor (which inhibits multiple […]

(Note: Craig Technical Consulting, Inc., or CTC, is the holder of all of our outstanding Class B common stock and will hold approximately 94.2% of the voting power of our outstanding capital stock following this offering. Carol Craig, our Chairwoman and Chief Executive Officer, is the sole owner of CTC.) Sidus Space is a space-as-a-service […]

We intend to focus on the media, entertainment and sports sectors. Our management team and Board of Directors (our “Board”) has had significant success sourcing, acquiring, growing and monetizing companies across these sectors. We have particular expertise in television broadcasting, and in local media generally. We believe this experience makes us well suited to identify, source, […]

We intend to focus on businesses with a connection to the Asian market. We will primarily seek to acquire one or more growth businesses with a total enterprise value of between $300 million and $600 million. Our focus will include these sectors: clean energy, the Internet and high technology, financial technology (FinTech), health care, consumer and […]

We intend to initially focus our search on identifying a prospective target business in North America within the renewable and transition energy sector, with a focus on pursuing growth opportunities that are driving the electrical power grid transition, both on the electrical supply and on the demand side for high-intensity electrical users, as well as seeking […]